Atherogenic autoantigen: Oxidized LDL complexes with β2-glycoprotein I

Eiji Matsuura, Kazuko Kobayashi, Takao Koike, Yehuda Shoenfeld, Munther A. Khamashta, Graham R V Hughes

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

β2-Glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies present in patients with antiphospholipid syndrome (APS). In 1997, we demonstrated that β2-GPI specifically binds to CU2+-oxidized low-density lipoprotein (oxLDL) and that the β2-GPI-oxLDL complex is subsequently targeted by anti-β2-GPI antibodies in vitro. Then ligands for β2-GPI were purified from oxLDL and characterized as omega-carboxylated 7-ketocholesteryl esters, such as 7-ketocholesteryl-9-carboxynonanoate (oxLig-1) and 7-ketocholesteryl-12-carboxy (keto) dodecanoate (oxLig-2). These ligands mediate to form oxLDL-β2-GPI complexes, and the complexes are taken up avidly by macrophages via anti-β2-GPI autoantibody-mediated phagocytosis. We recently demonstrated that appearance of autoantibodies against a complex of β2-GPI and oxLig-1 are highly associated with a history of arterial thrombosis. Serum oxLDL-β2-GPI complex and their IgG immune complexes are also risk factors arterial thrombosis in APS patients. There is increasing circumstantial evidence of autoimmune mechanism involving β2-GPI and oxLDL in the atherogenesis in APS.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalImmunobiology
Volume207
Issue number1
DOIs
Publication statusPublished - 2003

Fingerprint

Autoantigens
Glycoproteins
Antiphospholipid Syndrome
LDL Lipoproteins
Autoantibodies
Thrombosis
Laurates
oxidized low density lipoprotein
Ligands
Antiphospholipid Antibodies
Antigen-Antibody Complex
Phagocytosis
Atherosclerosis
Esters
Immunoglobulin G
Macrophages
Antigens
Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

Atherogenic autoantigen : Oxidized LDL complexes with β2-glycoprotein I. / Matsuura, Eiji; Kobayashi, Kazuko; Koike, Takao; Shoenfeld, Yehuda; Khamashta, Munther A.; Hughes, Graham R V.

In: Immunobiology, Vol. 207, No. 1, 2003, p. 17-22.

Research output: Contribution to journalArticle

Matsuura, Eiji ; Kobayashi, Kazuko ; Koike, Takao ; Shoenfeld, Yehuda ; Khamashta, Munther A. ; Hughes, Graham R V. / Atherogenic autoantigen : Oxidized LDL complexes with β2-glycoprotein I. In: Immunobiology. 2003 ; Vol. 207, No. 1. pp. 17-22.
@article{7a0799bba8cd4759b97c5fa9ebe23ba1,
title = "Atherogenic autoantigen: Oxidized LDL complexes with β2-glycoprotein I",
abstract = "β2-Glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies present in patients with antiphospholipid syndrome (APS). In 1997, we demonstrated that β2-GPI specifically binds to CU2+-oxidized low-density lipoprotein (oxLDL) and that the β2-GPI-oxLDL complex is subsequently targeted by anti-β2-GPI antibodies in vitro. Then ligands for β2-GPI were purified from oxLDL and characterized as omega-carboxylated 7-ketocholesteryl esters, such as 7-ketocholesteryl-9-carboxynonanoate (oxLig-1) and 7-ketocholesteryl-12-carboxy (keto) dodecanoate (oxLig-2). These ligands mediate to form oxLDL-β2-GPI complexes, and the complexes are taken up avidly by macrophages via anti-β2-GPI autoantibody-mediated phagocytosis. We recently demonstrated that appearance of autoantibodies against a complex of β2-GPI and oxLig-1 are highly associated with a history of arterial thrombosis. Serum oxLDL-β2-GPI complex and their IgG immune complexes are also risk factors arterial thrombosis in APS patients. There is increasing circumstantial evidence of autoimmune mechanism involving β2-GPI and oxLDL in the atherogenesis in APS.",
author = "Eiji Matsuura and Kazuko Kobayashi and Takao Koike and Yehuda Shoenfeld and Khamashta, {Munther A.} and Hughes, {Graham R V}",
year = "2003",
doi = "10.1078/0171-2985-00214",
language = "English",
volume = "207",
pages = "17--22",
journal = "Immunobiology",
issn = "0171-2985",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "1",

}

TY - JOUR

T1 - Atherogenic autoantigen

T2 - Oxidized LDL complexes with β2-glycoprotein I

AU - Matsuura, Eiji

AU - Kobayashi, Kazuko

AU - Koike, Takao

AU - Shoenfeld, Yehuda

AU - Khamashta, Munther A.

AU - Hughes, Graham R V

PY - 2003

Y1 - 2003

N2 - β2-Glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies present in patients with antiphospholipid syndrome (APS). In 1997, we demonstrated that β2-GPI specifically binds to CU2+-oxidized low-density lipoprotein (oxLDL) and that the β2-GPI-oxLDL complex is subsequently targeted by anti-β2-GPI antibodies in vitro. Then ligands for β2-GPI were purified from oxLDL and characterized as omega-carboxylated 7-ketocholesteryl esters, such as 7-ketocholesteryl-9-carboxynonanoate (oxLig-1) and 7-ketocholesteryl-12-carboxy (keto) dodecanoate (oxLig-2). These ligands mediate to form oxLDL-β2-GPI complexes, and the complexes are taken up avidly by macrophages via anti-β2-GPI autoantibody-mediated phagocytosis. We recently demonstrated that appearance of autoantibodies against a complex of β2-GPI and oxLig-1 are highly associated with a history of arterial thrombosis. Serum oxLDL-β2-GPI complex and their IgG immune complexes are also risk factors arterial thrombosis in APS patients. There is increasing circumstantial evidence of autoimmune mechanism involving β2-GPI and oxLDL in the atherogenesis in APS.

AB - β2-Glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies present in patients with antiphospholipid syndrome (APS). In 1997, we demonstrated that β2-GPI specifically binds to CU2+-oxidized low-density lipoprotein (oxLDL) and that the β2-GPI-oxLDL complex is subsequently targeted by anti-β2-GPI antibodies in vitro. Then ligands for β2-GPI were purified from oxLDL and characterized as omega-carboxylated 7-ketocholesteryl esters, such as 7-ketocholesteryl-9-carboxynonanoate (oxLig-1) and 7-ketocholesteryl-12-carboxy (keto) dodecanoate (oxLig-2). These ligands mediate to form oxLDL-β2-GPI complexes, and the complexes are taken up avidly by macrophages via anti-β2-GPI autoantibody-mediated phagocytosis. We recently demonstrated that appearance of autoantibodies against a complex of β2-GPI and oxLig-1 are highly associated with a history of arterial thrombosis. Serum oxLDL-β2-GPI complex and their IgG immune complexes are also risk factors arterial thrombosis in APS patients. There is increasing circumstantial evidence of autoimmune mechanism involving β2-GPI and oxLDL in the atherogenesis in APS.

UR - http://www.scopus.com/inward/record.url?scp=0037214899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037214899&partnerID=8YFLogxK

U2 - 10.1078/0171-2985-00214

DO - 10.1078/0171-2985-00214

M3 - Article

C2 - 12638898

AN - SCOPUS:0037214899

VL - 207

SP - 17

EP - 22

JO - Immunobiology

JF - Immunobiology

SN - 0171-2985

IS - 1

ER -